| Literature DB >> 34064347 |
Maria Musarra-Pizzo1, Rosamaria Pennisi1,2, Ichrak Ben-Amor1,3, Giuseppina Mandalari1, Maria Teresa Sciortino1.
Abstract
Viral infections are responsible for several chronic and acute diseases in both humans and animals. Despite the incredible progress in human medicine, several viral diseases, such as acquired immunodeficiency syndrome, respiratory syndromes, and hepatitis, are still associated with high morbidity and mortality rates in humans. Natural products from plants or other organisms are a rich source of structurally novel chemical compounds including antivirals. Indeed, in traditional medicine, many pathological conditions have been treated using plant-derived medicines. Thus, the identification of novel alternative antiviral agents is of critical importance. In this review, we summarize novel phytochemicals with antiviral activity against human viruses and their potential application in treating or preventing viral disease.Entities:
Keywords: drug resistance; natural bioactive compounds; novel antiviral drugs; viral infections
Year: 2021 PMID: 34064347 PMCID: PMC8147851 DOI: 10.3390/v13050828
Source DB: PubMed Journal: Viruses ISSN: 1999-4915 Impact factor: 5.048
Natural compounds and their antiviral targets against Hepatitis B virus.
| Natural Source | Compound | Hepatitis B Virus | Target | CC50 | IC50 | SI | Reference |
|---|---|---|---|---|---|---|---|
|
| Methanolic extracts | Hepatitis B virus | Inhibits viral entry, replication and maturation of HBV particles | [ | |||
|
| Methanolic extracts | Hepatitis B virus | |||||
|
| Crude extract | Hepatitis B virus | |||||
|
| Methanolic extracts | Hepatitis B virus | |||||
| Iminosugars 1-deoxynojirimycin (1-DNJ) | Hepatitis B virus | >50 mM | 2.96 mM | 208 | [ | ||
|
| Chloroform fraction | Hepatitis B virus | 19.67–20.92 mg/L | [ | |||
|
| Betulinic acid | Hepatitis B virus | Targeting host cellular factor | [ | |||
|
| CLL extract | Hepatitis B virus | [ | ||||
|
| LPRP-Et | Hepatitis B virus | [ |
CC50: Half maximal cytotoxic concentration; IC50: Half maximal inhibitory concentration; SI: Selectivity index = CC50/IC50.
Natural compounds and their antiviral targets against Herpesviruses.
| Natural Source | Compound | Herpesvirus | Target | CC50 | IC50 | SI | Reference |
|---|---|---|---|---|---|---|---|
| Curcumin | Herpes simplex virus-1 | Inhibits immediate-early gene expression | 484.2 μg/mL | 33.0 μg/mL | 14.6 | [ | |
|
| Quercetin | Herpes simplex virus-1 | Blocks viral binding and suppresses NF-kB | [ | |||
| Polyphenols-rich | Herpes simplex virus-1 | Inhibits expression of | 1.2 mg/mL | 0.4 mg/mL | 3 | [ | |
|
| Polyphenols-rich | Herpes simplex virus-1 | Blocks viral binding | 0.6 mg/mL | [ | ||
|
| Polyphenols-rich | Herpes simplex virus-1 | Reduction of cytopathic | [ | |||
|
| Homoharringtonine | Herpes simplex virus-1 | Targets the cellular | 139 nM | [ |
CC50: Half maximal cytotoxic concentration; IC50: Half maximal inhibitory concentration; SI: Selectivity index = CC50/IC50.
Natural compounds and their antiviral targets against Papillomaviruses.
| Natural Source | Compound | Papillomaviruses | Target | Reference |
|---|---|---|---|---|
|
| Curcumin | HPV-16 | Downregulating expression of | [ |
|
| Latex | HPV-16 | [ | |
| Basant | HPV-16 | Prevents the entry of HPV 16 in Hela cells | [ | |
|
| Epigallocatechin-3-gallate (EGCG) | HPV-16 | Promoting apoptosis and inhibiting cellular transcriptional factors | [ |
|
| Rhizome extract | HPV-16 | [ | |
|
| Stem extract | HPV-16 | [ | |
|
| Curcumin | HPV-18 | [ | |
|
| Leaves extract | HPV-18 | [ | |
|
| Crude extract | HPV-16 | [ | |
|
| Ethanolic extract | HPV-16 | [ |
Natural antiviral compounds against Adenoviruses.
| Natural Source | Compound | Adenoviruses | Target | CC50 | EC50-IC50 (µg/mL) | SI | Reference |
|---|---|---|---|---|---|---|---|
|
| Shikonin | AdV3 | Downregulation of capsid protein hexon expression | [ | |||
|
| Caffeic acid | AdV-3 | Inhibition of | 14.2 | 727 | [ | |
|
| p-coumaric acid | AdV-11 | 43.8 | 11.2 | |||
|
| Chlorogenic acid | AdV-3 | 76 | 52.6 | |||
|
| Ferulic acid | AdV-8 | 52.5 | 1.8 | |||
|
| Phenolic compounds | AdV-5 | 165.95 ± 12.7 | 6.62 ± 1.4 | 25.06 | [ | |
|
| n-butanol fraction | AdV-5 | 264.7 | 2.16 | 122.5 | [ | |
|
| Gallic acid | AdV-5 | 49.34 | 4.67 | 10.5 | ||
|
| Methanol extract | AdV-5 | [ | ||||
|
| Methanol/H2O extract | AdV-5 | |||||
|
| Quercetin | AdV-3 | 496.9 | 24.3 ± 4.9 | 20.4 | [ | |
|
| Crude aqueous extract | AdV-41 | 2696.8 | 733.9 | 3.7 | [ | |
|
| Crude aqueous extract | AdV-41 | 2649.6 | 3500 | |||
|
| Crude aqueous extract | AdV-41 | >960 | >960 | |||
|
| Apigenin | AdV-3 | 59.9 | 11.1 ± 0.9 | 5.4 | [ | |
|
| Linalool | AdV-3 | 177.1 | 24.4 ± 0.4 | 7.3 | ||
|
| Ursolic acid | AdV-8 | 100.5 | 4.2 ± 0.3 | 23.8 |
CC50: Half maximal cytotoxic concentration; EC50-IC50: Half maximal inhibitory concentration; SI: Selectivity index = CC50/IC50.
Natural compounds and their antiviral targets against Immunodeficiency virus.
| Natural Source | Compound | Immunodeficiency Virus | Target | CC50 | EC50-IC50 | SI | Reference |
|---|---|---|---|---|---|---|---|
| Griffithsin | HIV | Entry inhibitors | 0.043–0.63 nM | [ | |||
|
| Ascyanovirin-N | HIV | [ | ||||
|
| Mirabamide-A | HIV | 40–140 nM | [ | |||
|
| Betulinic acid Dihydro betulinic | HIV | Maturation inhibitors | 1.4 µM | 9.3 | [ | |
| Synthetic derivative of betulinic acid | Bevirimat | HIV | 25 μM | 7.8 nM | >2500 | [ | |
|
| Sennoside A | HIV | Reverse trascriptase and Integrase inhibitors | [ | |||
|
| Kuwanon-L | [ | |||||
|
| Patentiflorin A | HIV | 24−37 nM | [ | |||
|
| Calanolides | HIV | 0.1–0.4 µM | [ | |||
|
| Ingenol | HIV | Latency-reversing agents (LRAs) | [ | |||
|
| Procyanidin C1-flavonoids | HIV | [ |
CC50: Half maximal cytotoxic concentration; EC50-IC50: Half maximal inhibitory concentration; SI: Selectivity index = CC50/IC50.
Natural products against Influenza viruses.
| Natural Source | Compound | Influenza | Target | CC50 | EC50-IC50 | SI | Reference |
|---|---|---|---|---|---|---|---|
|
| Oligonol | H3N2 | Blocking (ROS)-dependent ERK | [ | |||
| Green tea | Catechins | H1N1 | Inhibiting RNA | [ | |||
| Aglaia | Silvestrol | H1N1 | Inhibitors of the | [ | |||
|
| Pateamine A | H1N1 | |||||
|
| Curcumin | H1N1 | Haemagglutinin | 43 µM | 0.47 µM | 92.5 | [ |
|
| Polyphenol rich extract | A549 | 50 μg/mL | [ | |||
|
| Punicalagin | H3N2 | [ | ||||
| Green tea | Epigallocatechin gallate | H1N1 | [ | ||||
| Blak tea | Theaflavin | H1N1 |
CC50: Half maximal cytotoxic concentration; EC50-IC50: Half maximal inhibitory concentration; SI: Selectivity index = CC50/IC50.
Natural products against Hepatitis C virus.
| Natural Source | Compound | HCV | Target | CC50 | EC50-IC50 (µg/mL) | SI or TI | Reference |
|---|---|---|---|---|---|---|---|
|
| Root extract | HCV | Inhibition of viral entry | 16.6 | 37 | [ | |
|
| Stem bark extract | 1.42 | 211 | ||||
|
| Leave extract | 13.17 | |||||
|
| Saikosaponin B2 | 740.4 ± 28.35 µM | 16.13 ± 2.41 µM | 45.9 | [ | ||
|
| Methanolic extract | 16.82 ± 1.89 | 215.4 ± 10.7 | 12.8 | |||
| Anthocyanidin | Delphinidin | 3.7 ± 0.8 μM | [ | ||||
|
| Ethyl acetate- | Suppression of the | 11.7 ± 0.7 | [ | |||
|
| Crude extracts | Inhibition of HCV NS3/4A protease | 19–77 µM | [ | |||
|
| Aqueous extract | Inhibition of HCV | 11 | [ | |||
|
| Flavonoids | [ | |||||
|
| 3-hydroxy caruilignan C | Reduction of HCV | 10.5 ± 1.2μM | [ | |||
|
| Methylene | Broad antiviral activity | 453 ± 0.00117 | [ | |||
|
| Phenolic | Suppression of HCV- | 7.5 ± 0.3 | [ | |||
|
| Naringenin | Release/Assembly | 109 μM | [ |
CC50: Half maximal cytotoxic concentration; EC50-IC50: Half maximal inhibitory concentration; SI: Selectivity index = CC50/IC50.
Natural compounds and their antiviral targets against Picornaviruses.
| Natural Source | Compound | Picornaviruses | Target | CC50 | EC50-IC50 | SI | Reference |
|---|---|---|---|---|---|---|---|
| Orobol 7-O-d-glucoside (O7G) | Human rhinovirus A | Broad | 100 | 0.58-8.80 | 12 | [ | |
|
| Crude aqueous extracts | Coxsackievirus B1 | 1469.3 | 105.7 ± 2.6 | 13.9 | [ | |
|
| Ethanolic extracts | Coxsackievirus B1 | 684.8 | 146.3 ± 2.9 | 4.7 | ||
|
| Gallic acid | Enterovirus 71 | 100 | 0.76 | 132 | [ | |
|
| Raoulic acid | Human rhinovirus 2 | 201.78 | 0.1 | [ | ||
|
| Ursolic acid | Coxsackievirus B1 | Targets viral structures and inhibits viral infection and | 100.5 | 0.4 ± 0.1 | 251 | [ |
|
| Silymarin | Enterovirus 71 | 160.20 ± 1.56 | 7.99 ± 3.0 | 20.05 | [ | |
|
| DCM fraction | Echoviruses E7 | 0.18 | 7.54 × 10−6 | 19.9 | [ | |
|
| Aqueous extract | Coxsackievirus B4 | 2800 | 0.8 | [ | ||
|
| Ethanol extract | Coxsackievirus B3 | 4 | 10 | [ | ||
|
| Quercetin-7-glucoside (Q7G) | Human rhinovirus 2 | >100 | 4.85–0.59 | >20.62 | [ | |
|
| Rosmarinic acid | Enterovirus A71 | 327.68 ± 14.43 | 31.57–114 | 2.87–10.36 | [ | |
|
| Epigallocatechin-3-gallate (EGCG) | Hepatitis virus A | [ | ||||
|
| Grape seed | Hepatitis virus A | [ | ||||
| Tannin ellagic acid | Human rhinovirus 2 | Targets host cellular factors | >100 | 38 ± 3.2 | >2.6 | [ | |
|
| Roots extract | Coxsackievirus B1 | 883.56 | 50.93 | [ | ||
| Mix of seven | Xiao chai hu tang | Coxsackievirus B1 | 945.75 | 50.93 | 18.92 | [ | |
|
| Orsaponin (OSW-1) | Enterovirus 71, Coxsackievirus A21 Human rhinovirus 2 | >100 nM | 2.4–9.4 nM | [ | ||
|
| Ginsenosides | Hepatitis virus A | [ |
CC50: Half maximal cytotoxic concentration; EC50-IC50: Half maximal inhibitory concentration; SI: Selectivity index = CC50/IC50.
Natural products against Noraviruses.
| Natural Source | Compound | Noroviruses | Target | CC50 | EC50-IC50 | SI | Reference |
|---|---|---|---|---|---|---|---|
|
| Juice | MNV-1 | Inhibiting | >0.1% | 0.005% | 20 | [ |
|
| Epigallocatechin gallate | FCV-F9 | 12 mg/mL | [ | |||
|
| Juice | MNV-1 | [ | ||||
|
| Carvacrol | MNV-1 | [ | ||||
|
| Persimmon tannin | HuNoV | Reduce genome | [ |
CC50: Half maximal cytotoxic concentration; EC50-IC50: Half maximal inhibitory concentration; SI: Selectivity index = CC50/IC50.
Natural compounds and their antiviral targets against Coronaviruses.
| Natural Source | Compound | Coronaviruses | Target | CC50 | EC50-IC50 | SI | Reference |
|---|---|---|---|---|---|---|---|
|
| Emodin | SARSCoV | Targeting viral proteins | 200 μM | [ | ||
|
| Ginsenoside-Rb1 | SARSCoV | [ | ||||
|
| Secomet-V | SARSCoV | [ | ||||
|
| Tetra-O-galloyl-β-D-glucose | SARSCoV | 1.08 mM | 4.5 μM | 240 | [ | |
|
| Saikosaponin B2 | HCoV-229E | 383.3 ± 0.2 µmol/L | 1.7 ± 0.1 | 221.9 | [ | |
|
| Bisbenzylisoquinoline alkaloids-tetrandrin | HCoVOC43 | 14.51 μM | 295.6 nM | >40 | [ | |
|
| Quercetin | SARS-CoV-2 | 3CLpro inhibitory activity | [ | |||
|
| Triterpenes | SARS-CoV-2 | 2.6–10.3 μM | [ | |||
| Black tea | 3-isotheaflavin-3-gallate (TF2B) and theaflavin-3,3’-digallate (TF3) | SARS-CoV-2 | ≤10 μM | [ | |||
|
| Sinigrin | SARS-CoV | >10,000 μM | 217 μM | [ | ||
|
| Curcumin | SARS-CoV-2 | Broad-spectrum activity | [ | |||
| Silvestrol | MERS-CoV | Inhibitors of viral mRNA translation | 1.3 nM | [ | |||
| CR-31-B (-) | HCoV-229E | [ | |||||
|
| Hippuristanol | HCoV-229E | [ | ||||
|
| Plitidepsin | SARS-CoV-2 | 1.99 −> 200 nM | 0.70–1.62 nM | [ |
CC50: Half maximal cytotoxic concentration; EC50-IC50: Half maximal inhibitory concentration; SI: Selectivity index = CC50/IC50.
Natural products against Flaviviruses, Togaviruses, and Filoviruses.
| Natural Source | Compound | Flavivirus | Target | CC50 | EC50-IC50 (µg/mL) | SI | Reference |
|---|---|---|---|---|---|---|---|
|
| Rutin | DENV-2 | Broad spectrum antiviral activity | <1000 | 362.68 | 2.75 | [ |
| Epigallocatechin | WNV | [ | |||||
|
| Galactomannans | YFV | [ | ||||
|
| Xindole alkaloids | DENV-2 | Immunomodulatory effects | [ | |||
| Baicalein | DENV and JEV | Inhibits the virus attachment | 115.2 ± 0.2 | 3.4–5.8 | 1.3–33.4 | [ | |
| Quercetin | DENV-2 | 28.9–35.7 | 7.07–8.74 | [ | |||
|
| Aqueous extract | DENV-2 | [ | ||||
|
| Curcumin | ZIKV | [ | ||||
|
| Silvestrol | ZIKV | Target the cellular factor eIF4A | [ | |||
|
|
|
|
|
|
|
|
|
| Green tea | Epigallocatechin gallate | CHIKV | Inhibits the virus attachment | 6.54 | [ | ||
| Baicalein | CHIKV | 1.891 | [ | ||||
|
| Berberine | CHIKV | Inhibits viral protein synthesis and viral replication | [ | |||
|
|
|
|
|
|
|
|
|
| Eugenol | EBOV | Broad spectrum antiviral activity | 1.3 μM | [ | |||
| p-anisaldehyde | EBOV | 2.8 μM | |||||
|
| Silvestrol | EBOV | Shutdown of viral protein synthesis | [ |
CC50: Half maximal cytotoxic concentration; EC50-IC50: Half maximal inhibitory concentration; SI: Selectivity index = CC50/IC50.